A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 369,500 shares of ATHA stock, worth $931,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares
369,500
Previous 298,600 23.74%
Holding current value
$931,140
Previous $725,000 39.59%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.24 - $4.15 $158,816 - $294,235
70,900 Added 23.74%
369,500 $1.01 Million
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.46 $27,104 - $47,970
19,500 Added 6.99%
298,600 $725,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $3.16 $67,260 - $111,864
-35,400 Reduced 11.26%
279,100 $563,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.59 $424,092 - $645,123
-179,700 Reduced 36.36%
314,500 $927,000
Q1 2023

May 15, 2023

BUY
$2.26 - $4.22 $366,345 - $684,062
162,100 Added 48.81%
494,200 $1.24 Million
Q4 2022

Feb 14, 2023

SELL
$2.76 - $3.37 $42,228 - $51,561
-15,300 Reduced 4.4%
332,100 $1.05 Million
Q3 2022

Nov 14, 2022

BUY
$3.12 - $3.96 $754,416 - $957,528
241,800 Added 228.98%
347,400 $1.03 Million
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $190,156 - $932,042
69,400 Added 191.71%
105,600 $322,000
Q1 2022

May 16, 2022

SELL
$8.96 - $13.51 $86,016 - $129,696
-9,600 Reduced 20.96%
36,200 $489,000
Q4 2021

Feb 14, 2022

SELL
$9.17 - $16.39 $266,847 - $476,949
-29,100 Reduced 38.85%
45,800 $597,000
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $360,510 - $436,946
39,400 Added 110.99%
74,900 $703,000
Q2 2021

Aug 16, 2021

SELL
$10.24 - $20.87 $165,888 - $338,094
-16,200 Reduced 31.33%
35,500 $364,000
Q1 2021

May 17, 2021

SELL
$16.9 - $29.77 $96,329 - $169,689
-5,700 Reduced 9.93%
51,700 $951,000
Q4 2020

Feb 16, 2021

BUY
$16.48 - $34.3 $945,952 - $1.97 Million
57,400 New
57,400 $1.97 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $95.3M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.